University of Basel

University of Basel Delivers First Biological Implants for Treatment of Cartilage Lesions and Osteoarthritis in Humans

Retrieved on: 
Wednesday, November 15, 2023
Research, Surgery, FDA, Clinical Trials, Stem Cells, Other Health, Biotechnology, Physical Therapy, Health, Science, Spotify, N, Sport, Knee, Teaching hospital, Life, Ankle, Patient, Rheumatoid arthritis, Knee pain, Arthritis, Ice, Nasal septum, University Children's Hospital Basel, Torture, Doctor of Philosophy, Skiing, Quality of life, Government, Inflammation, Crutch, Swiss National Science Foundation, Surgeon, Tissue engineering, Cartilage, Regenerative medicine, European, University Hospital of Basel, Arthralgia, University of Basel, Chondrocyte, Animal, OA, University, Elbow, Apple, Walking, Cell, Motion, Brain, Hope, Joint, PFOA, MD, Human, Swimming, Leg, Dentistry, Pharmaceutical industry, Osteoarthritis

The Department of Biomedicine at the University of Basel and the University Hospital Basel, today announced that it delivered the first surgical procedure to treat Osteoarthritis (OA) in humans.

Key Points: 
  • The Department of Biomedicine at the University of Basel and the University Hospital Basel, today announced that it delivered the first surgical procedure to treat Osteoarthritis (OA) in humans.
  • Chondrocytes are the cell building blocks for cartilage and the University of Basel team is using them to grow new cartilage.
  • Expanding beyond focal lesions six years ago, the University of Basel team treated two patients with advanced knee OA – patients who had been scheduled for knee joint replacement.
  • The team at the University of Basel are providing folks like us with new hope.

EQS-News: CHEPLAPHARM opens swiss subsidiary and wins Agnes Wasem as Managing Director

Retrieved on: 
Saturday, September 16, 2023
University of Basel, University, Cheplapharm Arzneimittel, Patient, King, Postgraduate diploma, Heavy equipment, Nursing, Binningen, Link Wasem

CHEPLAPHARM Arzneimittel GmbH, headquartered in Greifswald/Germany, has established a Swiss national subsidiary in Binningen.

Key Points: 
  • CHEPLAPHARM Arzneimittel GmbH, headquartered in Greifswald/Germany, has established a Swiss national subsidiary in Binningen.
  • Managing Director of the newly founded CHEPLAPHARM Schweiz GmbH is Agnes Wasem.
  • With Agnes Wasem, an experienced pharmaceutical manager takes over the management of the Swiss site.
  • Agnes Wasem has an excellent network in the Swiss pharmaceutical industry and especially in the greater Basel area.

Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
Wednesday, August 9, 2023
Stargardt disease, Hosting, Vitamin A, Patient, RPD, DAF, Ageing, University of Basel, Tissue, ARVO, Cash, University, Therapy, Food, Research, GA, Conference call, FDA, Conference, Safety, Retina, ODD, Eye, RBP4, Stargardt, Paratriathlon, Blood, Adolescence, KOL, AMD, Association for Research in Vision and Ophthalmology, United Kingdom, Pivotal, Fenretinide, Visual acuity, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DRAGON, Pharmaceutical industry, Fine chemical, Citrus, Ophthalmology, PHOENIX

ET

Key Points: 
  • ET
    SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced its financial results for the three months ended June 30, 2023 and provided a general business update.
  • Stargardt disease (STGD1): Accumulation of cytotoxic bisretinoids has been implicated in the onset and progression of STGD1.
  • For the three months ended June 30, 2023, general and administration expenses were $1.4 million compared to $0.9 million for the same period in 2022.
  • Belite Bio will host a webcast to discuss the Company’s financial results and provide a business update.

Quanterix’s Simoa® Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Neurological Disease Activity in Pediatric Patients

Retrieved on: 
Monday, July 31, 2023
Technology, Research, Neurology, Genetics, Other Technology, Other Health, Health, General Health, Science, European Medicines Agency, Professor, University, Partex Group, Blood, Spinal muscular atrophy, Lancet Neurology, AFL, Serum, Disability, Senior counsel, Parent, Person, Infection, Philip Niarchos, University Hospital of Basel, Limit, DSM-IV codes, Biomarker, Multiple sclerosis, Teaching hospital, Plasma, TEM Toloue-4, Protein, Patient, Data, Physician, HIV disease progression rates, Corporation, Ageing, Cardiology, University of Basel, News, The Lancet, Disease, Pharmaceutical industry, Medical imaging, Nursing

The Blood Neurofilament Light Chain (NfL) is an innovative biomarker that specifically indicates neuroaxonal health.

Key Points: 
  • The Blood Neurofilament Light Chain (NfL) is an innovative biomarker that specifically indicates neuroaxonal health.
  • However, its clinical application has been constrained due to the lack of established reference ranges for children and adolescents.
  • Accurate monitoring of neuroaxonal injury in neurologic and systemic diseases is of pivotal importance at population and individual patient levels.
  • “Measurement of serum NfL concentrations has the potential to substantially contribute to counseling of children and their parents and adolescents with neurological conditions, representing a significant driver of pediatric disability concerns worldwide.

Citizens, Inc. Celebrates the Retirement of Dr. Robert B. Sloan, Jr., and Acknowledges his Remarkable Contributions to the Company

Retrieved on: 
Friday, June 16, 2023
Princeton Theological Seminary, University of Basel, Houston Christian University, Theology, University, Life, Education, Audit, Compensation, Group of Six Artists, Policy, Athletic conference, Baylor University, CIA, Art, Growth, Master of Divinity, Cooper High School, Princeton University, NYSE, Conference, Management, Psychology, Citizenship

Joining the Board in 2007, Dr. Sloan has been an invaluable member, serving as the Chairman of the Board from 2016 to 2020.

Key Points: 
  • Joining the Board in 2007, Dr. Sloan has been an invaluable member, serving as the Chairman of the Board from 2016 to 2020.
  • Dr. Sloan has served as the President and Chief Executive Officer of Houston Christian University in Houston, Texas since 2006.
  • Born and raised in Coleman, Texas, Dr. Sloan's formative years were spent in Abilene, where he graduated from Cooper High School.
  • Pursuant to its Board refreshment policy, Citizens will continue to seek new qualified candidates to serve on its Board.

EQS-News: Secarna Pharmaceuticals announces publication of new preclinical data showing durable antitumor activity of LNAplus™-based ASOs that both stimulate the innate immune system and suppress PD-L1 expressi

Retrieved on: 
Monday, June 5, 2023
University of Geneva, Asos, DNA, ICIS, Human, University, Therapy, ICI, University of Basel, Neoplasm, DC, TLR9, Immunity, DC3 Music Group, Journal, Patient, Pathology, Mouse, ASO, Immunology, Immunotherapy, B cell, PD-L1, Toll-like receptor 9, Vaccine, Pharmaceutical industry, Cancer

TLR9 signaling is an important innate immune pathway that is relevant as a first-line defense mechanism against pathogens.

Key Points: 
  • TLR9 signaling is an important innate immune pathway that is relevant as a first-line defense mechanism against pathogens.
  • A drawback to this approach is that the TLR9 –mediated immune response is blunted by immediate upregulation of immune checkpoints such as PD-L1.
  • The combined downregulation of PD-L1 expression in a single-molecule approach resulted in exceptional antitumor activity in different tumor models.
  • “Our recently published data demonstrate the potential therapeutic effect of simultaneously targeting TLR9 and PD-L1, key modulators of the innate and adaptive immune system, respectively, with a bimodal ASO.

Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results

Retrieved on: 
Thursday, May 11, 2023
Insurance, Stargardt disease, Hosting, Vitamin A, Patient, RPD, DAF, University of Basel, Tissue, ARVO, Cash, University, Therapy, Food, Research, GA, Conference call, Paratriathlon, FDA, UCL Institute of Ophthalmology, Conference, Safety, Retina, ODD, Eye, RBP4, Stargardt, Blood, Adolescence, KOL, AMD, Phase 10, United Kingdom, Pivotal, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, DRAGON, Pharmaceutical industry, Dairy, Fine chemical, Citrus, Cryptocurrency, Ophthalmology, PHOENIX

ET

Key Points: 
  • ET
    SAN DIEGO, May 10, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases which have significant unmet medical needs, today announced its financial results for the first quarter ended March 31, 2023 and provided a general business update.
  • “We remain focused on advancing late-stage development of Tinlarebant and are pleased with the 60% enrollment seen to date in our pivotal Phase 3 DRAGON trial.
  • Among the minority subjects who did transition to DDAF lesions, Tinlarebant slowed the rate of progression compared to those reported in a natural history study.
  • Belite Bio will host a webcast to discuss the Company’s financial results and provide a business update.

Andrea Schenker-Wicki, President of the University of Basel, Switzerland’s oldest university and a leading global research university, will be honored by AUW on April 5

Retrieved on: 
Saturday, April 15, 2023
University of Zurich, University of Basel, National Agricultural Research, Extension, Education, and Economics Advisory Board, University, Radioactive decay, Education, National Science Board, Roche, ETH Zurich, BANGLADESH, Research, Doctor of Philosophy, Advisory board, Economics, Business administration, Student, AUW, Islam, Trustee, Natural Resources, University of Natural Resources and Life Sciences, Vienna, Law, University of Fribourg, Quality assurance, Jatiya Sangsad, Female, Medical device, Nursing, Management, Basel, Chemistry, Accreditation, Woman

Bangladesh's Information Minister Hon'ble Dr. Hasan Mahmud (who earned his PhD in Chemistry from Belgium) will speak as the Chief Guest in honoring Professor Schenker-Wicki.

Key Points: 
  • Bangladesh's Information Minister Hon'ble Dr. Hasan Mahmud (who earned his PhD in Chemistry from Belgium) will speak as the Chief Guest in honoring Professor Schenker-Wicki.
  • The AUW Choir will perform the national anthems of both Bangladesh and Switzerland to mark this special occasion.
  • "You are all welcome to Bangladesh," the Prime Minister said to the five Afghan women from AUW who met with her.
  • She is the recipient of an honorary doctorate from the University of Natural Resources and Life Sciences in Vienna.

Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1

Retrieved on: 
Tuesday, April 11, 2023
Stem cell, IOB, University, Johns Hopkins Hospital, Wilmer Ophthalmological Institute, Stargardt disease, Johns Hopkins School of Medicine, Geographic atrophy, RBP4, Vitamin A, Retina, Belite, Medical school, Moorfields Eye Hospital, Professor, Principal, University of Basel, Society, Safety, Pharmaceutical industry, Ophthalmology

SAN DIEGO, April 11, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company targeting eye diseases with significant unmet medical need, today announced it will host a virtual key opinion leader (KOL) event to discuss the RBP4 antagonist tinlarebant and its relevance in the treatment of Stargardt Disease 1.

Key Points: 
  • (Chairman of the Department of Ophthalmology, University of Basel) who will discuss the 18-month interim efficacy and safety data from Belite Bio’s Phase 2 trial evaluating tinlarebant (LBS-008) for the treatment of Stargardt disease (STGD1).
  • Tinlarebant has been granted Fast Track and Rare Pediatric Disease designations in the U.S., and orphan drug designation in the U.S. and Europe for STGD1.
  • He completed residency at Tübingen’s University Eye Hospital prior to a fellowship at Moorfields Eye Hospital & Institute of Ophthalmology in London.
  • A replay will be available approximately two hours after the event for 90 days.

Final Weeks to Register: 2 Day Pharmaceutical Regulatory Affairs in Asia Training Course - All Important Aspects of Gaining and Maintaining a Successful Marketing Authorisation (June 14-16, 2023) - ResearchAndMarkets.com

Retrieved on: 
Monday, April 10, 2023
Health, Pharmaceutical, Allen & Hanburys, Active ingredient, Pharma, Pharmaceutical formulation, London Organising Committee of the Olympic and Paralympic Games, University of Basel, University of Strathclyde, Head, DRA, Editorial board, Foreign, Commonwealth and Development Office, GSK plc, Biochemistry, Publication, Pharmaceutics, University of Manchester, Roche, Textbook, WHO, Novartis, Pharmaceutical industry, Pharmacy, Medtech, Chemistry

Prior to this, she worked at F. Hoffmann-La Roche in Switzerland where she gained several years' experience in industry basics and pre-clinical research.

Key Points: 
  • Prior to this, she worked at F. Hoffmann-La Roche in Switzerland where she gained several years' experience in industry basics and pre-clinical research.
  • Dr Alan Chalmers is a pharmacist with over 35 industrial experiences mainly in the field of pharmaceutical regulatory affairs.
  • He has also been director of two UK and Swiss registered pharmaceutical companies with specialised responsibility for international regulatory strategy.
  • Since 2012 he has been a member of the Editorial Board, Scrip Regulatory Affairs.